Vitiligo: A new side effect of everolimus therapy for metastatic renal cell carcinoma

Patients with metastatic renal cell carcinoma (mRCC) have always had a poor prognosis. Recently new targeted drugs were developed. A 73-year-old female patient affected from mRCC was assessed at our Department. She underwent before a multitargeted tyrosine kinase inhibitor (TKI) therapy, but she developed progressive liver metastases so she was treated after with everolimus, an allosteric inhibitor of the mammalian target of rapamycin (mTOR), but started developing depigmented lesions over the neck. Vitiligo is a common cutaneous disorder and drug-induced vitiligo is reported. Our case can suggest a new type of drug-induced vitiligo, caused by a melanocyte-specific mechanism of toxicity. © 2017, Australasian Medical Journal Pty Ltd. All rights reserved.